Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I.

Eur J Haematol

Laboratoire d'Histologie-Embryologie-Cytogénétique, Faculté de Médecine de Montpellier-Nîmes et Laboratoire de Cytologie Clinique et Cytogénétique, C.H.U. de Nîmes, France.

Published: November 2004

Interferon has been shown to be an effective treatment of congenital dyserythropoiesis type I (CDA-I), but the optimal dose and the feasibility of this treatment remains to be determined. Here, in a 9-yr follow-up of a single patient, we show that interferon remains active during such a long period. The optimal dose of conventional alpha interferon could be evaluated at 2 million units twice a week. Pegylated interferon could be used as well at a dose of 30 microg/wk. During interferon treatment, serum and erythrocyte ferritin levels decreased progressively, and remained inversely correlated with haemoglobin levels. On repeated liver biopsies, iron overload could be normalized. Low dose interferon is a long-term treatment of CDA-I, and allows a significant decrease in iron overload, that could be interesting even in patients who are only moderately anaemic.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2004.00310.xDOI Listing

Publication Analysis

Top Keywords

iron overload
12
alpha interferon
8
interferon treatment
8
congenital dyserythropoiesis
8
dyserythropoiesis type
8
optimal dose
8
interferon
7
treatment
5
long-term alpha
4
treatment effective
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!